2 unchanged sentences
On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300.0 million (net of taxes, fees and commissions).
−Removed: As of September 30, 2022, there was approximately $249.4 million (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program.
+Added: As of December 31, 2022, there was approximately $160.6 million (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program.
The share repurchase program has no specified expiration date.
3 unchanged sentences
The suspension was lifted effective February 10, 2022, enabling the Company to resume stock repurchases pursuant to the prior authorizations .
−Removed: During the first six months of fiscal 2023, we obtained 64,436 of our ordinary shares in the aggregate amount of $11.8 million in connection with share based compensation award programs.
−Removed: The following table summarizes the ordinary shares repurchase activity during the second quarter of fiscal 2023 under our ordinary share repurchase program:
+Added: During the first nine months of fiscal 2023, we obtained 74,897 of our ordinary shares in the aggregate amount of $13.1 million in connection with share based compensation award programs.
+Added: The following table summarizes the ordinary shares repurchase activity during the third quarter of fiscal 2023 under our ordinary share repurchase program:
Total Number of
8 unchanged sentences
Plans at Period End (in thousands)
−Removed: July 1-31 63,865 $ 212.79 63,865 $ 281,059
−Removed: August 1-31 68,838 209.93 68,838 265,109
−Removed: September 1-30 91,607 188.16 91,607 $ 249,371
+Added: October 1-31 61,629 $ 169.38 61,629 $ 238,932
+Added: November 1-30 25,000 181.59 25,000 234,392
+Added: December 1-31 396,204 186.18 396,204 $ 160,626
Total 482,833 (1) 183.80 (1) 482,833 160,626
4 unchanged sentences
001-38848), and incorporated herein by reference.)
−Removed: 10.1 Form of Deed of Indemnity for STERIS plc Directors and executive officers (Ireland and United Kingdom) (filed as Exhibit 10.1 to the STERIS plc Form 10-Q for the quarterly period ended June 30, 2022 (Commission File No.
−Removed: 001-38848) and incorporated herein by reference)*
−Removed: 10.2 Form of Deed of Indemnity for STERIS plc Directors and executive officers (Ireland)* (filed as Exhibit 10.2 to the STERIS plc Form 10-Q for the quarterly period ended June 30, 2022 (Commission File No.
−Removed: 001-38848) and incorporated herein by reference)*
−Removed: 10.3 Form of Indemnification Agreement between STERIS Corporation and certain director and executive officers of STERIS plc (filed as Exhibit 10.3 to the STERIS plc Form 10-Q for the quarterly period ended June 30, 2022 (Commission File No.
−Removed: 001-38848) and incorporated herein by reference)*
−Removed: 10.4 Description of STERIS Non-Employee Director Compensation Program*
15.1 Letter Re:
11 unchanged sentences
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
−Removed: *A management contract or compensatory plan or arrangement required to be filed as an exhibit hereto
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vice President, Controller and Chief Accounting Officer
−Removed: November 9, 2022
+Added: February 8, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.